Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

miRToTALL

Financiado

A microRNA-regulated cell death-inducing gene therapy for T-cell Acute Lymphobla...

A microRNA-regulated cell death-inducing gene therapy for T-cell Acute Lymphoblastic Leukemia T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Although outcome has improved throughout the years with the use of combined chemotherapy, the aggressive regimens required for treatment effica... ver más

31/05/2024

iMM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

iMM

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008676 FiCAT, desarrollo de una nueva tecnología de ingeniería gené... 384K€ Cerrado

TTT-therapy Targeting Acute Leukemia with TdT-TCR-T-cell therapy 150K€ Cerrado

SAF2010-20832 CARACTERIZACION GENETICA DE LAS CANCER-STEM-CELLS (CSC) EN T... 36K€ Cerrado

SAF2017-92632-EXP TERAPIA BASADA EN RNA MEDIANTE QUIMERAS APTAMERO-SIRNAS CONT... 85K€ Cerrado

ONCODESTROYER Targeting cancer vulnerabilities in acute leukemia 3M€ Cerrado

RTC2019-007028-1 Desarrollo preclínico y regulatorio de terapias CAR-T modula... 2K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2022-05-20
Fecha Fin: 2024-05-31

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Although outcome has improved throughout the years with the use of combined chemotherapy, the aggressive regimens required for treatment efficacy often lead to significant short- and long-term side effects. Moreover, a significant fraction of T-ALL patients relapse, which have extremely poor prognosis. The current project aligns with the core goal of our ERC Consolidator Grant IL7sigNETure (CoG-648455) to generate new targeted therapies for improved treatment of T-ALL, by aiming to develop a gene therapy cell death-inducing system (miRTo) that uses cell-endogenous microRNAs to regulate the expression of a cell death-inducing gene specifically in T-ALL cells (miRToTALL). While our innovative strategy has the potential to treat T-ALL patients more effectively and safely, it also displays market potential that extends well beyond T-ALL. This is because our technology is designed so that it can be adapted to the disease of choice or to particular disease subtypes through simple modifications, making it ideal for precision medicine in T-ALL, other cancers or other indications in which patients may benefit from the targeted delivery of a therapeutic gene. Our project will build upon the preliminary data that we have already generated, and make use of our models and expertise in the molecular and cellular biology of T-ALL, to provide preclinical validation of miRToTALL, laying the ground for a spin-off that will fully explore the miRTo technology platform.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores